Serum Levels of Some Trace Elements in Hepatocellular Carcinoma Patients
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Hepatocellular Carcinoma
Related studies linked through entity extraction aliases.
SBRT With Atezo/Bev for HCC
- Status
- RECRUITING
- Phase
- PHASE1
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
- Status
- RECRUITING
- Phase
- NA
Evaluating Novel Therapies in ctDNA Positive GI Cancers
- Status
- RECRUITING
- Phase
- PHASE3
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
- Status
- RECRUITING
- Phase
- PHASE3
Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
- Status
- RECRUITING
- Phase
- PHASE2
TACE With Dicycloplatin(TP21) in Unresectable HCC
- Status
- UNKNOWN
- Phase
- PHASE3
Neoadjuvant Anti-PD1 in HCC
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Antiviral Therapy for Patients With Liver Cancer After Surgery
- Status
- RECRUITING
- Phase
- N/A
Intra-arterial Perfusion in Interventional Radiology
- Status
- UNKNOWN
- Phase
- N/A
Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.
- Status
- TERMINATED
- Phase
- NA
Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma With Twin Cooled-wet Electrodes
- Status
- UNKNOWN
- Phase
- NA
Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies
- Status
- UNKNOWN
- Phase
- N/A
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- NA
TARGETed Therapy Drug MONITOring in DIGestive Oncology
- Status
- RECRUITING
- Phase
- NA
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Durvalumab and Tremelimumab in Resectable HCC
- Status
- RECRUITING
- Phase
- PHASE2
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2